Vaxcyte, Inc. $PCVX Shares Acquired by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP lifted its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 95.9% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 375,772 shares of the company's stock after acquiring an additional 183,986 shares during the quarter. Dimensional Fund Advisors LP owned 0.26% of Vaxcyte worth $21,836,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of PCVX. Parallel Advisors LLC boosted its stake in shares of Vaxcyte by 189.1% in the 1st quarter. Parallel Advisors LLC now owns 1,694 shares of the company's stock valued at $98,000 after buying an additional 1,108 shares during the period. Swiss National Bank raised its holdings in Vaxcyte by 1.2% in the first quarter. Swiss National Bank now owns 233,100 shares of the company's stock valued at $13,545,000 after acquiring an additional 2,700 shares in the last quarter. Jennison Associates LLC raised its holdings in Vaxcyte by 150.6% in the first quarter. Jennison Associates LLC now owns 1,698,011 shares of the company's stock valued at $98,671,000 after acquiring an additional 1,020,458 shares in the last quarter. California Public Employees Retirement System lifted its stake in Vaxcyte by 4.8% in the first quarter. California Public Employees Retirement System now owns 151,555 shares of the company's stock worth $8,807,000 after acquiring an additional 6,952 shares during the last quarter. Finally, Financiere des Professionnels Fonds d investissement inc. purchased a new position in Vaxcyte in the first quarter worth approximately $1,081,000. 96.78% of the stock is owned by institutional investors and hedge funds.

Vaxcyte News Summary

Here are the key news stories impacting Vaxcyte this week:

• Positive Sentiment: Quarterly loss beat expectations: Vaxcyte reported second-quarter 2026 EPS of negative $1.97, better than analysts’ consensus estimate of negative $2.06. However, the loss was wider than the negative $1.22 reported in the year-earlier quarter. Vaxcyte quarterly earnings release
• Positive Sentiment: Multiple clinical catalysts are ahead: Topline safety, tolerability and immunogenicity data from the VAX-31 adult Phase 3 OPUS-1 trial are expected in the fourth quarter of 2026. Results from OPUS-2 and OPUS-3 are expected in the first half of 2027, while infant VAX-31 data are expected by the end of the first half of 2027. Vaxcyte second-quarter business update
• Positive Sentiment: Strong liquidity supports development: Vaxcyte held approximately $2.5 billion in cash, cash equivalents and investments at June 30, 2026. The balance sheet reduces near-term financing concerns as the company advances its late-stage vaccine programs and VAX-A1.
• Neutral Sentiment: Institutional ownership remains high: Several funds, including Royal Bank of Canada, UBS Asset Management and Cetera Investment Advisers, increased their positions recently. Institutional investors and hedge funds collectively own approximately 96.8% of outstanding shares.
• Negative Sentiment: Executives reported stock sales: The CFO, COO and another insider sold a combined 29,250 shares worth roughly $1.6 million. The transactions were made under pre-arranged Rule 10b5-1 plans, limiting their significance, but the sales may still weigh modestly on sentiment. Vaxcyte insider selling report
• Negative Sentiment: Losses are expected to continue: Analysts forecast a full-year 2026 loss of approximately $7.91 per share, underscoring Vaxcyte’s dependence on successful clinical execution and future commercialization.

Insider Buying and Selling at Vaxcyte

In other news, COO Jim Wassil sold 2,250 shares of the stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $49.52, for a total transaction of $111,420.00. Following the completion of the sale, the chief operating officer owned 158,494 shares in the company, valued at approximately $7,848,622.88. This represents a 1.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Grant Pickering sold 22,461 shares of the firm's stock in a transaction dated Thursday, June 18th. The stock was sold at an average price of $52.50, for a total value of $1,179,202.50. Following the transaction, the chief executive officer directly owned 474,703 shares in the company, valued at approximately $24,921,907.50. This represents a 4.52% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 120,646 shares of company stock valued at $6,570,810. Company insiders own 3.30% of the company's stock.

Wall Street Analysts Forecast Growth

PCVX has been the topic of a number of recent analyst reports. Weiss Ratings reissued a "sell (d-)" rating on shares of Vaxcyte in a research report on Monday, July 6th. Wall Street Zen cut shares of Vaxcyte from a "sell" rating to a "strong sell" rating in a research report on Tuesday, April 28th. Finally, Zacks Research cut shares of Vaxcyte from a "hold" rating to a "strong sell" rating in a research report on Tuesday, July 14th. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company's stock. Based on data from MarketBeat, Vaxcyte has a consensus rating of "Hold" and a consensus target price of $86.00.

Vaxcyte Trading Up 5.3%

PCVX stock opened at $58.89 on Friday. The company has a market capitalization of $8.50 billion, a P/E ratio of -7.72 and a beta of 1.23. Vaxcyte, Inc. has a twelve month low of $29.08 and a twelve month high of $65.00. The business has a 50 day simple moving average of $53.72 and a 200-day simple moving average of $55.19.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last announced its earnings results on Wednesday, August 5th. The company reported ($1.97) EPS for the quarter, beating analysts' consensus estimates of ($2.06) by $0.09. During the same quarter last year, the firm earned ($1.22) earnings per share. Research analysts predict that Vaxcyte, Inc. will post -7.91 EPS for the current fiscal year.

About Vaxcyte

Vaxcyte, Inc NASDAQ: PCVX is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company's platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte's lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.

Want to see what other hedge funds are holding PCVX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vaxcyte, Inc. (NASDAQ:PCVX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source